(Q50554397)

15 March 2018

title

Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase. (English)

1 reference

15 March 2018

1 reference

1 reference

1 reference

1 reference

Mosaburo Kainuma

1

1 reference

15 March 2018

Norihiro Furusyo

2

1 reference

15 March 2018

Koichi Azuma

3

1 reference

15 March 2018

Eiji Kajiwara

4

1 reference

15 March 2018

Kazuhiro Takahashi

5

1 reference

15 March 2018

Hideyuki Nomura

6

1 reference

15 March 2018

Yuichi Tanabe

7

1 reference

15 March 2018

Takeaki Satoh

8

1 reference

15 March 2018

Toshihiro Maruyama

9

1 reference

15 March 2018

Makoto Nakamuta

10

1 reference

15 March 2018

Kazuhiro Kotoh

11

1 reference

15 March 2018

Shinji Shimoda

12

1 reference

15 March 2018

Jun Hayashi

13

1 reference

15 March 2018

Kyushu University Liver Disease Study (KULDS) Group

14

1 reference

15 March 2018

publication date

22 November 2011

1 reference

15 March 2018

published in

Hepatology Research

1 reference

15 March 2018

volume

42

1 reference

15 March 2018

issue

1

1 reference

15 March 2018

page(s)

33-41

1 reference

15 March 2018

A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Chronic hepatitis C in patients with persistently normal alanine transaminase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Updated definitions of healthy ranges for serum alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Therapy of hepatitis C: patients with normal aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon alpha-2a and ribavirin: a multicentric study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Detection and quantitation of HCV RNA using real-time PCR after automated sample processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Ribavirin concentration in the later stages of 48 week pegylated interferon-alpha2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Serum lipids and their associations with viral levels and liver disease severity in a treatment-naïve chronic hepatitis C type 1-infected cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

Effectiveness of interferon treatment for patients with chronic hepatitis C virus infection and normal aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00907.X

10.1111/J.1872-034X.2011.00907.X

21 January 2018

Identifiers

DOI

1 reference

15 March 2018

1 reference

15 March 2018